All lobbying filings

THE MCMANUS GROUP

Lobbying for FULCRUM THERAPEUTICS · Rare disease biopharma company

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · Massachusetts · House · Senate · $40,000.00 income · posted Oct 20, 2025

Official filing document

Bills named in this filing 2

HR 1796
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
S 735
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025

Lobbying activity 1

Health Issues

Education and advocacy regarding sickle cell disease, including H.R. 1796/S. 735- Sickle Cell Disease and Other Heritable Blood Disorders, Research, Surveillance, Prevention, and Treatment Act of 2025.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.